However, current guidelines recommend that innovative medication classes, such as GLP-1 Ras and SGLT-2is, should be used in T2DM patients regardless of their glycemic control, with this approach aiming to reduce CV and renal risks. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.